Brief: Corline Biomedical Expectes Positive EBITDA In 2027
BRIEF-Corline Biomedical Expectes Positive EBITDA In 2027 Nov 4 (Reuters) - Corline Biomedical AB CLBIO.ST:
ISSUES FINANCIAL FORECAST FOR 2026 AND GUIDANCE FOR 2027
FORECASTS REVENUE OF SEK 16 MLN IN 2026, SEK 30 MLN IN 2027; EBITDA POSITIVE IN 2027
KARDIUM PARTNERSHIP ESTIMATED TO GENERATE 2 BILLION SEK TOTAL REVENUE, SEK 200 MLN ANNUAL POTENTIAL
KARDIUM TO OPEN COSTA RICA FACILITY EXPECTED TO CREATE ABOUT 1,000 JOBS
BUSINESS PLAN FULLY FINANCED; NO ADDITIONAL EXTERNAL CAPITAL REQUIRED
Source text: ID:nGNE2LZrvl
Further company coverage: CLBIO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln